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ABSTRACT
Administration of opioid drugs such as heroin produces several
immunosuppressive effects, including decreases in natural
killer (NK) cell activity, lymphocyte proliferative responses, and
nitric oxide production. Interestingly, opioids have been shown
to alter many immune parameters indirectly by modulating the
immunoregulatory actions of the central nervous system. Re-
cently, it has been demonstrated that morphine inhibits NK cell
activity through a neural pathway that requires the activation of
dopamine D1 receptors in the nucleus accumbens shell. The
present study examined whether the nucleus accumbens also
mediates the effects of heroin, a more commonly abused opi-
oid, on several parameters of immune status in Lewis rats. The
results showed that bilateral administration of the dopamine
D1 receptor antagonist R-()-7-chloro-8-hydroxy-3-methyl-
1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrochloride
(SCH-23390; 0.015 and 0.15 g/side) into the nucleus accum-
bens shell blocked decreases in splenic NK activity produced
by heroin (3 mg/kg s.c.) but did not attenuate the suppression
of splenocyte proliferative responses to concanavalin-A or li-
popolysaccharide (LPS). A subsequent experiment was per-
formed to evaluate the effect of D1 receptor antagonism on
LPS-induced expression of inducible nitric-oxide synthase
(iNOS) in vivo. These results showed that intra-accumbens
SCH-23390 administration prevented heroin-induced reduc-
tions of iNOS mRNA expression in spleen, liver, and lung tis-
sues and attenuated the suppression of nitric oxide levels in
plasma. Collectively, these findings indicate that nucleus ac-
cumbens dopamine D1 receptors are critically involved in her-
oin-induced immune alterations.
Opioid drug use is associated with adverse health conse-
quences. Heroin abusers display abnormalities in basic im-
mune parameters and have high rates of viral, bacterial, and
fungal infections (Louria et al., 1967; Govitrapong et al.,
1998). Although the high incidence of infectious diseases
among abusers is commonly attributed to increased pathogen
exposure or insalubrious behaviors, opioids exert potent im-
munomodulatory effects that may further enhance infection
susceptibility. Controlled studies in humans demonstrate
that morphine produces immunosuppressive effects in
healthy, nondrug-using subjects (Yeager et al., 1995), and
clinical reports indicate that higher doses of opioid analgesics
are associated with greater frequencies of infectious compli-
cations among burn victims and patients that underwent
cardiac surgery (El Solh et al., 2006; Schwacha et al., 2006).
Thus, the use of opioids, whether for therapeutic or recre-
ational purposes, may directly influence resistance to infec-
tious diseases.
In animal models, morphine has been shown to suppress a
variety of immune parameters, but the mechanisms under-
lying these effects are not fully understood (Lysle et al., 1993;
Lockwood et al., 1994). Opioids modulate immunity in a
highly complex manner by interacting with opioid receptors
expressed by multiple cell types throughout the body. For
example, in vitro studies show that morphine can inhibit
macrophage phagocytosis and interferon- production
through direct interactions with immunocyte opioid recep-
tors (Peterson et al., 1987; Szabo et al., 1993). In addition,
This work was supported in part by the National Institutes of Health
National Institute on Drug Abuse [Grants DA13371, DA07481]; the National
Institutes of Health National Institute on Drug Abuse [Grant DA00334] (Re-
search Scientist Development Award to D. T. L.); and the National Institutes
of Health National Institute on Drug Abuse [Grant DA019323] (predoctoral
fellowship to T.B.S.).
This work was part of the doctoral dissertation of Saurer TB (2007) Neu-
roimmune mechanisms of opioid-mediated immunomodulation. Ph.D. thesis,
The University of North Carolina at Chapel Hill, Chapel Hill, NC. Parts of this
work were previously presented at the following conference: Saurer TB, Ijames
SG, and Lysle DT (2008) Neuroimmune mechanisms of heroin-induced alter-
ations in iNOS, Society on NeuroImmune Pharmacology 14th Annual Confer-
ence; 2008 March 12–15; Charleston, SC. Society on NeuroImmune Pharma-
cology, Tampa, FL.
Article, publication date, and citation information can be found at
http://jpet.aspetjournals.org.
doi:10.1124/jpet.108.148627.
ABBREVIATIONS: NK, natural killer; iNOS, inducible nitric-oxide synthase; LPS, lipopolysaccharide; SCH-23390 R-()-7-chloro-8-hydroxy-3-
methyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrochloride; Con-A, concanavalin A; RT-PCR, reverse transcriptase-polymerase chain
reaction; ANOVA, analysis of variance; SKF38393, 2,3,4,5-tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; CNS, central nervous system.
0022-3565/09/3293-1040–1047$20.00
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS Vol. 329, No. 3
Copyright © 2009 by The American Society for Pharmacology and Experimental Therapeutics 148627/3469384
JPET 329:1040–1047, 2009 Printed in U.S.A.
1040
morphine administration in vivo has been shown to inhibit
NK activity and lymphocyte proliferative responses indi-
rectly by acting within the brain to disrupt the immunoregu-
latory functions of the nervous system (Weber and Pert,
1989; Hernandez et al., 1993). Neural modulation of immu-
nity by morphine is a well documented phenomenon that
involves both neuroendocrine and autonomic efferent path-
ways (Fuchs and Pruett, 1993; Fecho et al., 1996).
Our laboratory has recently begun examining the role of
central dopamine receptors in opioid-induced immune alter-
ations. Similar to virtually every drug of abuse, opioids stim-
ulate dopamine transmission in the nucleus accumbens (Pon-
tieri et al., 1995), and it is widely recognized that such
alterations in dopamine signaling modulate the motivational
and reinforcing properties of opioids. Interestingly, at least
some of morphine’s immunomodulatory effects are also de-
pendent on dopamine transmission. Specifically, the activa-
tion of dopamine D1 receptors in the nucleus accumbens shell
is necessary for morphine to suppress splenic NK cell activity
and sufficient to inhibit NK responses in the absence of
morphine (Saurer et al., 2006a). Thus, nucleus accumbens
dopamine receptors seem to play a critical role in neuroim-
mune modulation by morphine.
Heroin administration has also been shown to inhibit im-
mune parameters such as NK activity, lymphocyte prolifer-
ation, and nitric oxide production (Fecho and Lysle, 2000;
Lysle and How, 2000). Although heroin is more commonly
abused than morphine, only a limited number of studies have
examined the mechanisms of heroin’s immunomodulatory
effects. A common assumption is that the biological effects of
these drugs are the same, as heroin (diacetylmorphine) is
readily metabolized to morphine. Although similar in many
respects, there are several key pharmacological differences
between heroin and morphine. For example, heroin produces
different subjective psychological effects in humans (Martin
and Fraser, 1961), has a more rapid onset of action (Olden-
dorf et al., 1972), and is more potent in producing behavioral
effects (Kaiko et al., 1981). Furthermore, because the unique
heroin metabolite 6-monoacetylmorphine has been shown to
produce analgesic effects by engaging different opioid recep-
tor populations than morphine (Rady et al., 1991; Rossi et al.,
1996), it is possible that heroin may also elicit immune al-
terations via different receptor mechanisms.
The goals of the present study were two-fold. First, based
on our prior investigations indicating the importance of the
nucleus accumbens in the immunological effects of morphine
(Saurer et al., 2006a), we sought to determine whether the
nucleus accumbens was also involved in heroin’s suppressive
effects on splenic NK activity and mitogen-induced lympho-
cyte proliferation. Second, to further explore the mechanisms
of heroin’s effects in the context of an in vivo immune re-
sponse, the present study assessed the role of nucleus accum-
bens D1 receptors in heroin-induced alterations of inducible
nitric-oxide synthase (iNOS) expression. The iNOS enzyme
has a critical role in disease resistance and possesses potent
antimicrobial effects owing to the generation of nitric oxide.
Under normal conditions, iNOS is expressed at low levels,
but its expression is markedly up-regulated in response to
infection or immune challenge. In the present study, iNOS
production was induced with lipopolysaccharide (LPS), the
major immunogenic component of Gram-negative bacteria.
Importantly, this model permits the evaluation of heroin’s
effects on a critical immune response in vivo.
Materials and Methods
Animals. Adult male Lewis rats weighing approximately 200 to
250 g were purchased from Charles River Laboratories (Raleigh,
NC). Upon arrival, animals were individually housed and main-
tained on a reverse 12-h light/dark cycle. Animals were habituated to
handling and the colony room environment for 2 weeks before any
experimental manipulation. Food and water were available ad libi-
tum throughout the experiment.
Drugs. Heroin (diacetylmorphine sulfate; National Institute on
Drug Abuse, Bethesda, MD) and SCH-23390 (Sigma-Aldrich, St.
Louis, MO) were dissolved in sterile 0.9% saline. For all experiments,
heroin or saline injections were administered in a 1.0 ml/kg volume.
Surgery. Stereotaxic surgeries were performed under anesthesia
induced with a 0.2-ml intramuscular injection of a 1:1 (v/v) mixture
of ketamine hydrochloride (100 mg/ml) and xylazine hydrochloride
(20 mg/ml). Animals receiving SCH-23390 microinjections into the
nucleus accumbens shell were implanted with bilateral 26-gauge
guide cannulae (Plastics One, Roanoke, VA) aimed at the following
coordinates: AP, 1.7; ML, 0.8, and DV, 5.4 (coordinates ex-
pressed as millimeters from bregma). Animals were given a 1-week
recovery period before testing.
Drug Administration. The optimal dose of heroin for producing
immune alterations was first established by conducting a dose-re-
sponse analysis. In the heroin dose-response experiment, rats were
assigned to one of five groups (n  4/group). Each group received a
single subcutaneous injection of heroin at a dose of 0, 1, 3, 5, or 10
mg/kg. The range of heroin doses used in the present study was
selected based on previously published findings showing that heroin
significantly inhibits NK activity and lymphocyte mitogenic re-
sponses at 1 mg/kg, with much more pronounced effects at 10 mg/kg
(Fecho and Lysle, 2000).
A subsequent experiment was performed to evaluate the involve-
ment of nucleus accumbens dopamine D1 receptors in heroin’s ef-
fects. For this manipulation, animals were assigned to one of six
groups (n  5–6/group) in which they received a bilateral microin-
jection of SCH-23390 (0, 0.015, or 0.15 g/side) into the nucleus
accumbens shell immediately before injection with saline or heroin
(3 mg/kg s.c.). The doses of SCH-23390 used in the current study
were selected based on our previous work that showed that mor-
phine-induced suppression of NK activity is partially attenuated at a
dose of 0.015 g/side and fully blocked at a dose of 0.15 g/side
(Saurer et al., 2006a). In addition, because the goal of the microin-
jection studies was to determine whether SCH-23390 administration
would block the effects of heroin, we selected the 3-mg/kg dose of
heroin, because this was the lowest dose that produced the most
prominent and consistent effects across all immune parameters ex-
amined in the dose-response experiment. Microinjections of SCH-
23390 were delivered in a 0.5-l volume per side via a bilateral
33-gauge injector that protruded 2 mm beyond the tip of the guide
cannula (final coordinates, AP, 1.7; ML,  0.8; and DV, 7.8).
Microinjections were performed over a 30-s period using a microsy-
ringe pump (Harvard Apparatus Inc., Holliston, MA), and the injec-
tor was left in place for 1 min to allow diffusion of the drug away from
the injection site.
To evaluate the role of nucleus accumbens D1 receptors in the
effects of heroin on lipopolysaccharide (LPS)-induced iNOS produc-
tion, animals were assigned to one of six groups (n  3–4), in which
they received bilateral microinjections of SCH-23390 (0, 0.015, or
0.15 g/side) into the nucleus accumbens shell as described above.
Immediately after microinjection, rats were administered heroin (3
mg/kg s.c.) or saline in conjunction with a 1-mg/kg injection of LPS
(serotype 055:B5; Difco, Detroit, MI). Six hours after the injection of
LPS, animals were sacrificed by cervical dislocation. Blood samples
were taken from the abdominal aorta for the determination of
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plasma nitrite/nitrate levels, and spleen, liver, and lung tissues were
collected for RNA extraction. This experiment was replicated using
the same design, and the data were combined for analysis (n 
6–7/group).
After drug treatment and sacrifice, Alcian Blue dye was injected
via the cannula, and brains were removed and stored in a 4% para-
formaldehyde solution for 2 days. Brains were then transferred to a
30% sucrose solution for several days for cryoprotection, frozen, and
stored at 80°C for subsequent analysis. Accurate cannula place-
ments were verified by examination of 50-m coronal tissue sections
under a light microscope. Only animals with placements within the
targeted region were included in the analysis.
Tissue Collection. For ex vivo assessments of splenic NK activity
and mitogen-induced proliferation, rats were sacrificed by cervical
dislocation 1 h after heroin or saline injection. The spleen was re-
moved and placed in 7 ml of RPMI 1640 tissue culture medium
supplemented with 10 mM HEPES, 2 mM glutamine, and 50 g/ml
gentamicin (supplemented RPMI 1640 medium; Invitrogen, Carls-
bad, CA). Each spleen was prepared as a single-cell suspension by
gently pressing the tissue between two sterile, frosted microscope
slides in supplemented RPMI 1640 medium enriched with 10% fetal
bovine serum (complete RPMI 1640 medium; Invitrogen). Splenic
leukocytes were counted using a Hemavet 850 cell analyzer (CDC
Technologies Inc., Oxford, CT), and cell suspensions were adjusted to
5  106 leukocytes/ml by diluting with complete RPMI 1640 medium.
NK Cell Activity Assay. Splenic NK cell activity was assessed
using a standard chromium release assay according to previously
published procedures (Fecho et al., 1993; Lysle et al., 1993). Adjusted
splenocyte suspensions were coincubated with the murine T-cell
lymphoma YAC-1. The YAC-1 target cells were labeled by incubation
for 70 min with 200 Ci of sodium chromate-51 [51Cr]. YAC-1 cells
were then washed three times with complete RPMI 1640 medium to
remove exogenous [51Cr]. Splenic leukocytes were used as effectors
and were plated in triplicate at 10, 5, 2.5, and 1.25  105 cells/well of
a 96-well plate. Labeled targets were diluted and plated at 1  104
cells/well to give effector/target (E:T) ratios of 100:1, 50:1, 25:1, and
12.5:1. After 5-h incubation at 37°C in a humidified CO2 incubator,
the amount of [51Cr] released into the supernatant was determined
using a gamma counter (model 1272 CliniGamma; GE Healthcare,
Chalfont St. Giles, Buckinghamshire, UK). Percentage of specific
lysis at all E:T ratios was used to calculate lytic units. One lytic unit
is defined as the number of splenic leukocytes necessary to lyse 20%
of the target cells. Results are reported as the number of lytic units
per 107 effector cells.
Splenocyte Proliferation Assay. Mitogen stimulation assays
were completed following previously published procedures (Fecho et
al., 1993; Lysle et al., 1993). Splenic T- and B-lymphocyte prolifera-
tion was induced with the mitogens concanavalin-A (Con-A) and LPS
(Sigma-Aldrich), respectively. One hundred microliters of the ad-
justed splenocyte suspensions was pipetted in triplicate into micro-
titer plate wells containing final concentrations of 0, 0.5, and 5.0
g/ml Con-A and 0.5 and 5.0 g/ml LPS to provide background,
suboptimal, and optimal mitogen concentrations. All statistical anal-
yses were performed on the results from the 5.0-g/ml concentra-
tions of Con-A and LPS, because previously published data have
established that this concentration elicits optimal proliferation re-
sponses under the present parameters (Lysle et al., 1993). Spleno-
cyte cultures were then incubated for 48 h at 37°C in a humidified
CO2 incubator. Each culture well was pulsed with 1 Ci of [
3H]thy-
midine during the last 5 h of the incubation period. Cultures were
then harvested onto glass fiber filter paper using an automatic
96-well cell harvester (Tomtec, Orange, CT). The amount of [3H]thy-
midine incorporated into the DNA of proliferating cells was mea-
sured using a liquid scintillation counter (model 1205; PerkinElmer
Wallac, Waltham, MA) and is expressed as the mean of the triplicate
dpm for the samples from each rat.
Real-Time RT-PCR. To determine iNOS expression, real-time
reverse transcriptase-polymerase chain reaction (RT-PCR) was per-
formed. Total RNA was extracted from a section of each spleen, liver,
and lung using TRI-Reagent (Molecular Research Center, Cincin-
nati, OH), and RNA was quantified spectrophotometrically
(GeneQuant II; GE Healthcare). For the RT-PCR, reverse transcrip-
tion was performed using oligo(dT)18 primer and Moloney murine
leukemia virus-reverse transcriptase following the protocol of the
advantage RT-for-PCR kit from Clontech (Mountain View, CA). PCR
amplifications were performed using the Fast Start DNA Master
SYBR Green I real-time PCR kit (Roche Diagnostics, Indianapolis,
IN) and the LightCycler instrument (Roche Diagnostics). All reaction
components were prepared in a master mix solution, with each
reaction using a 20-l mix placed in glass capillary tubes designed
for the LightCycler system. The PCR primer set for iNOS, 5-CCCT-
TCCGAAGTTTCTGGCAGCAGC-3 and 5-GGGTGTCAGAGTCTT-
GTGCCTTTGG-3, was synthesized by the Nucleic Acids Core Facil-
ity (Lineberger Cancer Center, University of North Carolina at
Chapel Hill, Chapel Hill, NC). The analysis of fluorescence levels in
standards and samples over the course of 40 amplification cycles was
used to derive the number of copies of the target molecule in each
sample, based on an external standard curve. The cycle tempera-
tures were 95, 60, and 72°C for the denaturing, annealing, and
extending, respectively, with cycle times of 15, 5, and 25 s, respec-
tively. Fluorescence level was determined at the end of the extending
phase for each cycle of PCR. In addition, assessments of housekeep-
ing gene expression, cyclophilin, were made to ensure comparable
quality of RNA among samples. The sequence of the cyclophilin
primers was 5-CCAAGACTGAGTGGCT-3 and 5-AGATTA-
CAGGGTATTGCG-3. The data are expressed as the ratio of iNOS
mRNA copies (per 10 ng of cDNA) to cyclophilin copy number based
on the standard curve using the LightCycler software (Roche Diag-
nostics). Furthermore, to confirm the nature of amplification prod-
uct, a melt curve analysis was conducted after the final PCR cycle.
Nitrite Assay. To provide an additional assessment of nitric oxide
production, the level of nitrite/nitrate in plasma was determined
using the Griess reagent assay. Nitrate and nitrite are formed non-
enzymatically when nitric oxide is exposed to oxygen; thus, plasma
levels of these products reflect the level of nitric oxide production. To
determine total nitrite/nitrate levels, nitrate was first converted to
nitrite using nitrate reductase in the presence of NADPH and flavin
adenine dinucleotide. Specifically, 6 l of plasma was mixed with 44
l of distilled H2O, 20 l of 0.31 M phosphate buffer, pH 7.5, 10 l of
0.86 mM NADPH (Sigma-Aldrich), 10 l of 0.11 mM flavin adenine
dinucleotide (Sigma-Aldrich), and 10 l of 1.0 U/ml nitrate reductase
(Roche Diagnostics) in individual wells of a 96-well plate. Samples
were incubated for 1.5 h at room temperature. Then, 200 l of Griess
reagent consisting of a 1:1 (v/v) solution of 1% sulfanilamide in 5.0%
phosphoric acid and 0.1% N-(1-napthyl)ethyl-enedamine dihydro-
chloride in distilled water was added to the samples. After incuba-
tion for 10 min at room temperature, absorbance was measured at
550 nm using a plate reader (model EL312; BioTek Instruments,
Winooski, VT). The total micromolar concentration of nitrite was
then determined for each sample based on a standard curve. Recov-
ery of nitrate is greater than 95% in this assay.
Statistics. Results from the heroin-dose effect study were ana-
lyzed using one-way analysis of variance. Data analysis for all do-
pamine antagonist experiments was performed using two-way anal-
ysis of variance, with experimental replication entered into the
model as a covariate to control for interassay variability in the
measured parameters. For the two-way analysis, the first factor was
SCH-23390 dosage and the second factor was drug treatment, i.e.,
heroin or saline. For all data sets, planned comparisons were per-
formed in accordance with a priori hypotheses that SCH-23390
would antagonize the effects of heroin. Planned comparisons in each
analysis consisted of pairwise comparisons of means between heroin
treatment groups and saline treatment groups at each level of the
factor “SCH-23390 dosage.” All analyses were performed with the
	-level of significance set at p 
 0.05.
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Results
Heroin Dose-Response Analysis. The optimal dose of
heroin for producing immune alterations was first estab-
lished by conducting a dose-response analysis. The results of
this experiment are displayed in Fig. 1. Analysis of variance
yielded a significant main effect of dose on NK cell activity,
indicating that heroin reduced NK activity [F(4,15)  16.22;
p 
 0.0001]. Furthermore, planned comparisons showed that
heroin significantly decreased cytolytic activity at every dose
examined. Heroin administration also suppressed splenocyte
proliferative responses to Con-A and LPS (Fig. 1). There was
a significant main effect of heroin on proliferation induced by
Con-A [F(4,14)  36.51; p  0.0001]. Planned comparisons
further showed that heroin significantly decreased mitogenic
responses to Con-A at each dose examined. Analysis of vari-
ance also revealed a significant main effect of heroin on
LPS-induced proliferation [F(4,14)  33.89; p 
 0.0001], and
this suppressive effect of heroin was evident at each dose
tested.
Effect of D1 Receptor Antagonism on NK Activity.
The effect of SCH-23390 administration into the nucleus
accumbens shell on heroin-induced decreases in NK activity
is shown in Fig. 2. Analysis of variance revealed significant
main effects of heroin treatment [F(1,27)  18.15; p 
 0.001]
and SCH-23390 dose [F(2,27)  6.02; p 
 0.01]. Planned
comparisons demonstrated that heroin significantly reduced
NK cell activity in the control groups that received saline
microinjections [F(1,27)  16.48; p 
 0.001]. Planned com-
parisons also revealed that both doses of SCH-23390 blocked
the effects of heroin, because there were no significant dif-
ferences between heroin and saline groups among animals
that received SCH-23390.
Effect of D1 Receptor Antagonism on Splenocyte
Proliferation. Figure 3 (top) shows the effect of SCH-23390
administration into the nucleus accumbens shell on heroin-
induced reductions in proliferative responses to Con-A. The
analysis yielded a significant main effect of heroin treatment
[F(1,27)  27.00; p 
 0.0001], but there was not a significant
main effect of SCH-23390 dose [F(2,27)  0.33; p  0.05].
Moreover, there was no significant interaction between her-
oin and SCH-23390 treatment [F(2,27)  0.01; p  0.05].
Planned comparisons further indicated that heroin signifi-
cantly decreased Con-A induced proliferation at each dose of
SCH-23390 tested.
The effect of SCH-23390 administration on heroin-induced
decreases mitogenic responses to LPS is shown in the bottom
panel of Fig. 3. Analysis of variance revealed a significant
main effect of heroin [F(1,27)  37.62; p 
 0.0001]. There was
no effect of SCH-23390 treatment [F(2,27)  0.44; p  0.05],
nor was there a significant interaction between SCH-23390
dose and heroin treatment [F(2,27)  0.02; p  0.05].
Planned comparisons indicated that heroin’s suppressive ef-
fect on LPS-induced proliferation was not blocked by SCH-
23390 at any dose, because all heroin-treated groups were
significantly decreased relative to the corresponding saline
control groups.
Effect of D1 Receptor Antagonism on iNOS Expres-
sion. A final study was performed to examine whether D1
receptors in the nucleus accumbens shell also play a role in
the effects of heroin on the production of iNOS in vivo. LPS-
induced expression of iNOS mRNA in spleen, liver, and lung
tissues is shown in Fig. 4. Analysis of variance revealed a
significant interaction between SCH-23390 dosage and her-
oin treatment in the spleen [F(2,33)  4.50; p 
 0.05], liver
[F(2,33)  9.74; p 
 0.001], and lung [F(2,33)  7.91; p 

0.01], indicating that SCH-23390 altered the suppressive
effect of heroin in all tissues. Planned comparisons further
revealed that among animals that received saline microinjec-
tions, heroin treatment significantly reduced iNOS levels
compared with saline in the spleen [F(1,33)  6.02; p 
 0.05],
liver [F(1,33)  14.07; p 
 0.001], and lung [F(1,33)  12.11;
p 
 0.01]. Importantly, planned comparisons also showed
that heroin- and saline-treated groups that received the high-
Fig. 1. Effects of heroin dose on splenic immune measures. Data from the cytotoxicity assay are expressed as lytic units (mean  S.E.). Data from
proliferation assays are expressed as disintegrations per minute (mean  S.E.). , p 
 0.05; , p 
 0.001 compared with saline-treated control group.
Fig. 2. Effect of D1 receptor antagonism in the nucleus accumbens on
heroin-induced suppression of NK cell activity. Rats received bilateral
microinjections of saline or SCH-23390 into the nucleus accumbens shell
before a subcutaneous injection of heroin. Data are expressed as lytic
units (mean  S.E.). , p 
 0.001 compared with the saline-treated
control group that received an equivalent dose of SCH-23390.
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est dose of SCH-23390 were not significantly different with
respect to iNOS expression in the spleen [F(1,33)  0.23; p 
0.05], liver [F(1,33)  3.96; p  0.05], or lung [F(1,33)  1.37;
p  0.05].
Effect of D1 Receptor Antagonism on Plasma Nitrite/
Nitrate Levels. SCH-23390 administration into the nucleus
accumbens shell also attenuated the effects of heroin on
LPS-induced nitric oxide levels in the plasma as determined
by the Greiss reagent assay (Fig. 5). Analysis of variance
revealed a significant interaction between SCH-23390 dos-
age and heroin treatment [F(2,33)  7.03; p 
 0.01], indicat-
ing that the effect of heroin differed as a function of SCH-
23390 dosage. Planned comparisons demonstrated that
heroin significantly reduced plasma nitrite/nitrate levels
compared with saline treatment among animals that re-
ceived saline microinjections [F(1,33)  50.80; p 
 0.0001].
SCH-23390 microinjections did not completely block heroin’s
effect however, because planned comparisons showed signif-
icant differences between heroin and saline groups at the
highest dose of SCH-23390 [F(1,33)  5.29; p 
 0.05].
Discussion
Although there is substantial evidence that opioids disrupt
parameters of immune status by interacting with -opioid
receptors in the central nervous system, the neural mecha-
nisms that underlie these effects are poorly understood. Al-
terations in dopamine signaling produced by opioid exposure
may be particularly relevant to opioid-induced immune dys-
function given reports that mesoaccumbens dopamine neu-
rons modulate the immune response (Deleplanque et al.,
1994; Devoino et al., 1997). Previous work from our labora-
tory has demonstrated that morphine-induced suppression of
NK cell activity is mediated by dopamine D1 type receptors
located in the nucleus accumbens shell, whereas dopamine
D2 type receptors do not seem to be involved (Saurer et al.,
2006a). The present study supports and extends our previous
work by showing that D1 receptors in the nucleus accumbens
shell also mediate the inhibitory effects of heroin on splenic
NK activity and LPS-induced nitric oxide production.
Before the examination of dopamine receptor mechanisms
Fig. 3. Effect of D1 receptor antagonism in the nucleus accumbens on
heroin-induced decreases in splenocyte mitogenic responses. Rats re-
ceived bilateral microinjections of SCH-23390 into the nucleus accum-
bens shell before a subcutaneous injection of saline or heroin. Data are
expressed as disintegrations per minute (mean  S.E.). , p 
 0.01
compared with the saline group that received the same dose of SCH-
23390.
Fig. 4. Effect of D1 receptor antagonism in the nucleus accumbens on
heroin-induced reductions of iNOS mRNA expression. Rats received mi-
croinjections of SCH-23390 into the nucleus accumbens shell before sub-
cutaneous injections of saline or heroin in conjunction with LPS admin-
istration. Data are expressed as the ratio of iNOS mRNA expression to
expression of the housekeeping gene cyclophilin (mean  S.E.). , p 

0.05; , p 
 0.01; , p 
 0.001 compared with the saline group that
received an equivalent dose of SCH-23390.
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in the present study, a dose-response analysis was con-
ducted to determine the lowest dose of heroin needed to
induce an optimal suppression of functional immune mea-
sures, i.e., NK activity and splenocyte proliferative re-
sponses to the T-cell mitogen Con-A, and the B-cell mito-
gen LPS. The heroin doses used in the present study (1, 3,
5, and 10 mg/kg) were selected based on a previous report
that heroin significantly inhibits these parameters at
doses as low as 1 mg/kg, with more pronounced effects at
10 mg/kg (Fecho and Lysle, 2000). The present results
reveal that heroin induces a maximal suppression of NK
activity at doses of 1 mg/kg or higher, whereas doses of 3
mg/kg or higher produce the most prominent effects on
lymphocyte proliferative responses. Therefore, heroin was
administered at a dose of 3 mg/kg in the subsequent ma-
nipulations involving SCH-23390 microinjections.
The present findings indicate the effects of heroin on im-
mune status involve both dopamine-dependent and dopa-
mine-independent neural mechanisms. These results are
consistent with previous reports that the centrally mediated
effects of opioids on different immune parameters involve
distinct neuroimmune pathways. For example, microinjec-
tion of morphine into the periaqueductal gray matter inhibits
splenic NK activity but does not affect lymphocyte prolifera-
tion (Weber and Pert, 1989; Lysle et al., 1996). Furthermore,
administration of -adrenergic blockers selectively prevents
reductions in splenic lymphocyte proliferation after mor-
phine treatment (Fecho et al., 1993), whereas neuropeptide
Y1 receptor antagonism selectively blocks the suppression of
NK activity (Saurer et al., 2006b). The current results pro-
vide additional evidence that distinct neural pathways are
involved in these effects by showing that SCH-23390 admin-
istration abolishes the suppressive effect of heroin on NK
activity but does not prevent decreases in lymphocyte prolif-
erative responses to Con-A or LPS. These results corroborate
our previous findings that the stimulation of dopamine re-
ceptors with the selective D1 agonist SKF38393 inhibits
splenic NK activity (Saurer et al., 2006a) without affecting
lymphocyte proliferation (unpublished observations).
In contrast to current knowledge regarding opioid effects
on NK cytolytic activity and lymphocyte proliferative re-
sponses, the physiological mechanisms by which opioids mod-
ulate nitric oxide production in response to endotoxin (LPS)
exposure are poorly understood. Some studies have shown
that opioids can modulate LPS-induced nitric oxide produc-
tion in vitro (Iuvone et al., 1995; Singhal et al., 1998),
whereas others demonstrate the involvement of central opi-
oid mechanisms (Gomez-Flores et al., 1999). Further compli-
cating efforts to elucidate precise mechanisms are reports
that morphine may augment (Martucci et al., 2007) or inhibit
(Iuvone et al., 1995) the generation of nitric oxide in response
to LPS. Such discrepancies are probably because of numer-
ous factors, including, but not limited to, the dose of mor-
phine, the duration of exposure, the cell types or tissues
under investigation, the time point at which nitric oxide is
measured, and the temporal relationship between opioid ex-
posure and LPS stimulation. Moreover, because immuno-
modulation involves complex interactions between many
physiological systems, removal of immune cells from the
organism for in vitro assays may preclude the influence of
endocrine and autonomic systems that regulate immune
functions under normal physiological conditions. Therefore,
it is imperative to validate in vitro and ex vivo findings with
in vivo models. The results of studies using in vivo models of
LPS-induced endotoxemia in the rat demonstrate that heroin
administration reduces protein and mRNA levels of iNOS in
several organs and decreases plasma nitrite/nitrate levels
(Lysle and How, 2000; Lanier et al., 2002). The present
experiments extend these findings and provide the first evi-
dence that these effects of heroin are mediated by the CNS by
showing that reductions of LPS-induced iNOS production in
spleen, liver, and lung tissues are dependent on the activa-
tion of dopamine D1 receptors in the nucleus accumbens. In
addition to identifying the nucleus accumbens as a critical
neural substrate of the effects of heroin on in vivo immune
responses, these findings are important because they suggest
that the dopaminergic input to the nucleus accumbens per se
may have a fundamental role in immune regulation.
Although the results of the current study implicate the
CNS in modulating heroin-induced alterations of iNOS pro-
duction, it is possible that heroin may have produced con-
comitant local elevations of nitric oxide in peripheral cells
that were not detectable at the tissue level. As mentioned
above, several investigators have shown that morphine aug-
ments macrophage-derived nitric oxide production under
basal and LPS-stimulated conditions in vitro (Singhal et al.,
1998; Martucci et al., 2007). However, because heroin metab-
olites act at multiple receptor sites throughout the body, any
changes in iNOS production that are observed in the in vivo
milieu should reflect the overall influence of heroin, despite
potentially contrasting central and peripheral influences, or
discordant effects on individual cell types. Although specula-
tive, one possibility is that the centrally mediated inhibitory
effects of heroin on iNOS production may override any pe-
ripheral or direct stimulatory effects. It is interesting to note
that animals that received the highest dose of SCH-23390 in
combination with heroin actually showed a trend toward
increased iNOS expression compared with the controls (Fig.
4). Because SCH-23390 treatment alone did not increase
iNOS levels, it is possible that blockade of the central path-
ways responsible for heroin’s inhibitory influence may have
unmasked a more subtle peripheral stimulatory effect. An
important issue for future studies will be to tease apart the
relative contributions of central versus peripheral influences
of heroin on iNOS production in vivo.
Fig. 5. Effect of D1 receptor antagonism in the nucleus accumbens on
heroin-induced reductions of plasma nitrite/nitrate. Data are expressed
as the plasma nitrite/nitrate concentration in micromolar (mean  S.E.).
, p 
 0.05; , p 
 0.01; , p 
 0.001 compared with the saline group
that received an equivalent dose of SCH-23390.
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An interesting question raised by the current findings is
how alterations in central dopamine receptor activity trans-
late to changes in peripheral immune function. Although the
efferent pathway from the nucleus accumbens to peripheral
immune compartments has not been specifically identified,
there is accumulating evidence that the sympathetic nervous
system may be involved. For example, neural control of
splenic NK cell activity is mediated primarily by the sympa-
thetic nervous system via the splenic nerve (Irwin et al.,
1990; Katafuchi et al., 1993), and prior investigations have
demonstrated that neuropeptide Y, a sympathetic transmit-
ter in the peripheral nervous system, mediates reductions in
NK cell activity produced by either systemic morphine or
intra-accumbens D1 agonist administration (Saurer et al.,
2006b). The nucleus accumbens shell has direct connections
with several hypothalamic nuclei such as the lateral hypo-
thalamus, which are known to modulate splenic NK activity
(Heimer et al., 1991; Wenner et al., 1996). Thus, one possi-
bility is that dopamine transmission within the nucleus ac-
cumbens modulates splenic NK activity through interactions
with hypothalamic autonomic regulatory centers. Although
less is known about the central mechanisms that modulate
iNOS expression in peripheral tissues such as the spleen,
liver, and lung, the sympathetic nervous system may like-
wise play a major role. Interestingly, stress-induced suppres-
sion splenic cytokine responses to LPS were shown to be
mediated by the sympathetic nervous system (Meltzer et al.,
2004). Given the many similarities between the effects of
stress and exogenous opioids on immune function, it is
tempting to speculate that similar mechanisms mediate her-
oin’s effect on nitric oxide production. Indeed, several stres-
sor-induced immune alterations are actually mediated by
endogenous opioids (Shavit et al., 1984; Tseng et al., 2005),
and both exogenous opioids and acute stressors induce
marked increases in nucleus accumbens dopamine levels
(Rougé-Pont et al., 1993; Pontieri et al., 1995). However,
further research is necessary to evaluate whether elevations
in accumbens dopamine modulate stress-induced immune
alterations in a manner similar to heroin.
Overall, the present study provides substantial evidence
for the involvement of the dopaminergic input to the nucleus
accumbens in heroin-induced immune alterations. In addi-
tion, the present findings are the first to demonstrate that
the effects of heroin on nitric oxide production are modulated
by the CNS. Given the importance of nitric oxide in resis-
tance to infectious diseases and immune regulation, the cur-
rent findings suggest that heroin-induced alterations in
dopamine signaling may be directly related to the immuno-
logical abnormalities and increased infection susceptibility
among heroin users. Furthermore, as elevations in dopamine
transmission are a common feature among various immuno-
modulatory stimuli, these findings have may have important
implications regarding endogenous physiological mecha-
nisms of neuroimmune regulation.
References
Deleplanque B, Vitiello S, Le Moal M, and Neveu PJ (1994) Modulation of immune
reactivity by unilateral striatal and mesolimbic dopaminergic lesions. Neurosci
Lett 166:216–220.
Devoino L, Alperina E, Galkina O, and Ilyutchenok R (1997) Involvement of brain
dopaminergic structures in neuroimmunomodulation. Int J Neurosci 91:213–228.
El Solh AA, Bhora M, Pineda L, and Dhillon R (2006) Nosocomial pneumonia in
elderly patients following cardiac surgery. Respir Med 100:729–736.
Fecho K, Dykstra LA, and Lysle DT (1993) Evidence for -adrenergic-receptor
involvement in the immunomodulatory effects of morphine. J Pharmacol Exp Ther
265:1079–1087.
Fecho K, Maslonek KA, Dykstra LA, and Lysle DT (1996) Evidence for sympathetic
and adrenal involvement in the immunomodulatory effects of acute morphine
treatment in rats. J Pharmacol Exp Ther 277:633–645.
Fecho K, Nelson CJ, and Lysle DT (2000) Phenotypic and functional assessments of
immune status in the rat spleen following acute heroin treatment. Immunophar-
macology 46:193–207.
Fuchs BA and Pruett SB (1993) Morphine induces apoptosis in murine thymocytes
in vivo but not in vitro: involvement of both opiate and glucocorticoid receptors.
J Pharmacol Exp Ther 266:417–423.
Gomez-Flores R, Suo JL, and Weber RJ (1999) Suppression of splenic macrophage
functions following acute morphine action in the rat mesencephalon periaqueduc-
tal gray. Brain Behav Immun 13:212–224.
Govitrapong P, Suttitum T, Kotchabhakdi N, and Uneklabh T (1998) Alterations of
immune functions in heroin addicts and heroin withdrawal subjects. J Pharmacol
Exp Ther 286:883–889.
Heimer L, Zahm DS, Churchill L, Kalivas PW, and Wohltmann C (1991) Specificity
in the projection patterns of accumbal core and shell in the rat. Neuroscience
41:89–125.
Hernandez MC, Flores LR, and Bayer BM (1993) Immunosuppression by morphine
is mediated by central pathways. J Pharmacol Exp Ther 267:1336–1341.
Irwin M, Hauger RL, Jones L, Provencio M, and Britton KT (1990) Sympathetic
nervous system mediates central corticotropin-releasing factor induced suppres-
sion of natural killer cytotoxicity. J Pharmacol Exp Ther 255:101–107.
Iuvone T, Capasso A, D’Acquisto F, and Carnuccio R (1995) Opioids inhibit the
induction of nitric oxide synthase in J774 macrophages. Biochem Biophys Res
Commun 212:975–980.
Kaiko RF, Wallenstein SL, Rogers AG, Grabinski PY, and Houde RW (1981) Anal-
gesic and mood effects of heroin and morphine in cancer patients with postoper-
ative pain. N Engl J Med 304:1501–1505.
Katafuchi T, Ichijo T, Take S, and Hori T (1993) Hypothalamic modulation of splenic
natural killer cell activity in rats. J Physiol 471:209–221.
Lanier RK, Ijames SG, Carrigan KA, Carelli RM, and Lysle DT (2002) Self-
administration of heroin produces alterations in the expression of inducible nitric
oxide synthase. Drug Alcohol Depend 66:225–233.
Lockwood LL, Silbert LH, Fleshner M, Laudenslager ML, Watkins LR, and Maier SF
(1994) Morphine-induced decreases in in vivo antibody responses. Brain Behav
Immun 8:24–36.
Louria DB, Hensle T, and Rose J (1967) The major medical complications of heroin
addiction. Ann Intern Med 67:1–22.
Lysle DT and How T (2000) Heroin modulates the expression of inducible nitric oxide
synthase. Immunopharmacology 46:181–192.
Lysle DT, Coussons ME, Watts VJ, Bennett EH, and Dykstra LA (1993) Morphine-
induced alterations of immune status: dose dependency, compartment specificity
and antagonism by naltrexone. J Pharmacol Exp Ther 265:1071–1078.
Lysle DT, Hoffman KE, and Dykstra LA (1996) Evidence for the involvement of the
caudal region of the periaqueductal gray in a subset of morphine-induced alter-
ations of immune status. J Pharmacol Exp Ther 277:1533–1540.
Martin WR and Fraser HF (1961) A comparative study of physiological and subjec-
tive effects of heroin and morphine administered intravenously in postaddicts.
J Pharmacol Exp Ther 133:388–399.
Martucci C, Franchi S, Lattuada D, Panerai AE, and Sacerdote P (2007) Differential
involvement of RelB in morphine-induced modulation of chemotaxis, NO, and
cytokine production in murine macrophages and lymphocytes. J Leukoc Biol
81:344–354.
Meltzer JC, MacNeil BJ, Sanders V, Pylypas S, Jansen AH, Greenberg AH, and
Nance DM (2004) Stress-induced suppression of in vivo splenic cytokine produc-
tion in the rat by neural and hormonal mechanisms. Brain Behav Immun 18:262–
273.
Oldendorf WH, Hyman S, Braun L, and Oldendorf SZ (1972) Blood-brain barrier:
penetration of morphine, codeine, heroin, and methadone after carotid injection.
Science 178:984–986.
Peterson PK, Sharp B, Gekker G, Brummitt C, and Keane WF (1987) Opioid-
mediated suppression of interferon-gamma production by cultured peripheral
blood mononuclear cells. J Clin Invest 80:824–831.
Pontieri FE, Tanda G, and Di Chiara G (1995) Intravenous cocaine, morphine, and
amphetamine preferentially increase extracellular dopamine in the “shell” as
compared with the “core” of the rat nucleus accumbens. Proc Natl Acad Sci U S A
92:12304–12308.
Rady JJ, Roerig SC, and Fujimoto JM (1991) Heroin acts on different opioid receptors
than morphine in Swiss Webster and ICR mice to produce antinociception. J Phar-
macol Exp Ther 256:448–457.
Rossi GC, Brown GP, Leventhal L, Yang K, and Pasternak GW (1996) Novel receptor
mechanisms for heroin and morphine-6 beta-glucuronide analgesia. Neurosci Lett
216:1–4.
Rougé-Pont F, Piazza PV, Kharouby M, Le Moal M, and Simon H (1993) Higher and
longer stress-induced increase in dopamine concentrations in the nucleus accum-
bens of animals predisposed to amphetamine self-administration. A microdialysis
study. Brain Res 602:169–174.
Saurer TB, Carrigan KA, Ijames SG, and Lysle DT (2006a) Suppression of natural
killer cell activity by morphine is mediated by the nucleus accumbens shell.
J Neuroimmunol 173:3–11.
Saurer TB, Ijames SG, and Lysle DT (2006b) Neuropeptide Y Y1 receptors mediate
morphine-induced reductions of natural killer cell activity. J Neuroimmunol 177:
18–26.
Schwacha MG, McGwin G Jr, Hutchinson CB, Cross JM, Maclennan PA, and Rue
LW 3rd (2006) The contribution of opiate analgesics to the development of infec-
tious complications in burn patients. Am J Surg 192:82–86.
Shavit Y, Lewis JW, Terman GW, Gale RP, and Liebeskind JC (1984) Opioid
1046 Saurer et al.
peptides mediate the suppressive effect of stress on natural killer cell cytotoxicity.
Science 223:188–190.
Singhal PC, Sharma P, Kapasi AA, Reddy K, Franki N, and Gibbons N (1998)
Morphine enhances macrophage apoptosis. J Immunol 160:1886–1893.
Szabo I, Rojavin M, Bussiere JL, Eisenstein TK, Adler MW, and Rogers TJ (1993)
Suppression of peritoneal macrophage phagocytosis of Candida albicans by opi-
oids. J Pharmacol Exp Ther 267:703–706.
Tseng RJ, Padgett DA, Dhabhar FS, Engler H, and Sheridan JF (2005) Stress-
induced modulation of NK activity during influenza viral infection: role of glu-
cocorticoids and opioids. Brain Behav Immun 19:153–164.
Weber RJ and Pert A (1989) The periaqueductal gray-matter mediates opiate-
induced immunosuppression. Science 245:188–190.
Wenner M, Kawamura N, Miyazawa H, Ago Y, Ishikawa T, and Yamamoto H (1996)
Acute electrical stimulation of lateral hypothalamus increases natural killer cell
activity in rats. J Neuroimmunol 67:67–70.
Yeager MP, Colacchio TA, Yu CT, Hildebrandt L, Howell AL, Weiss J, and Guyre PM
(1995) Morphine inhibits spontaneous and cytokine-enhanced natural killer cell
cytotoxicity in volunteers. Anesthesiology 83:500–508.
Address correspondence to: Dr. Donald T. Lysle, Department of Psychol-
ogy, Davie Hall, CB#3270, University of North Carolina at Chapel Hill, Chapel
Hill, NC 27599-3270. E-mail: dlysle@email.unc.edu
Nucleus Accumbens and Heroin-Induced Immune Alterations 1047
